Trial Profile
A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera) and Tocilizumab (RoActemra) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 18 Mar 2013 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov record.
- 11 Mar 2013 Planned end date changed from 1 May 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.